Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Prepaid Assets (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Prepaid Assets for 12 consecutive years, with $6.4 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets rose 2038.81% year-over-year to $6.4 million; the TTM value through Mar 2026 reached $6.4 million, up 2038.81%, while the annual FY2025 figure was $5.5 million, N/A changed from the prior year.
  • Prepaid Assets hit $6.4 million in Q1 2026 for Crescent Biopharma, up from $5.5 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $6.4 million in Q1 2026 and bottomed at $299232.0 in Q1 2025.
  • Average Prepaid Assets over 5 years is $1.8 million, with a median of $1.3 million recorded in 2023.
  • Year-over-year, Prepaid Assets crashed 65.2% in 2025 and then soared 2038.81% in 2026.
  • Crescent Biopharma's Prepaid Assets stood at $399861.0 in 2022, then skyrocketed by 399.65% to $2.0 million in 2023, then crashed by 60.04% to $798274.0 in 2024, then skyrocketed by 584.35% to $5.5 million in 2025, then rose by 17.15% to $6.4 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $6.4 million, $5.5 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.